CEO Praveen Tipirneni was paid $8,907,684 in fiscal year 2023, ↓ down 15.3% from fiscal year 2022, the 74th percentile of its disclosed peer group (SEC filing 0001679363-24-000035 ↗): executive and director compensation, incentive-plan design, equity activity, and governance — every figure in this brief is traceable to its exact location in the company’s SEC filing — the document, the section, the page, and the table, linked directly.
$8,907,684 ↓ Praveen Tipirneni total, FY2023 | 74th CEO pay percentile vs peers | — CEO-to-median pay ratio | 98.55% Say-on-pay support, latest vote |
Track this company's pay every filing: join the Pro seat waitlist
Velarion Pro: every company page, peer tools and exports, one seat — $1,200/year
Ask our research desk — $99, 24h, every figure cited to its filing.
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Praveen Tipirneni | $613,502 | $0 | $3,742,960 | $4,121,756 | $412,966 | $0 | $16,500 | $8,907,684 |
| Chief Executive Officer | ||||||||
| Bruce Rogers | 546,000 | 0 | 1,931,748 | 2,089,936 | 294,840 | 0 | 16,500 | 4,879,024 |
| President, Interim Principal Executive Officer | ||||||||
| Marc Schegerin | 488,800 | 0 | 1,861,964 | 2,015,056 | 263,952 | 0 | 16,500 | 4,646,272 |
| Chief Financial Officer and Chief Operating Officer | ||||||||
| Robert Farrell | 425,000 | 0 | 1,608,204 | 1,777,004 | 204,000 | 0 | 16,500 | 4,030,708 |
| Senior Vice President of Finance and Chief Accounting Officer | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
| Named executive officer | FY2023 total | FY2022 total | FY2021 total | Δ FY2022→2023 |
|---|---|---|---|---|
| Praveen Tipirneni | $8,907,684 | $10,520,145 | — | ↓ −1,612,461 |
| Bruce Rogers | 4,879,024 | 5,259,046 | — | ↓ −380,022 |
| Marc Schegerin | 4,646,272 | 4,349,052 | — | ↑ +297,220 |
| Robert Farrell | 4,030,708 | — | — | — |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
You have just read Morphic Holding's Summary Compensation Table. The whole free brief as a PDF, emailed now, with every figure cited — then a few short notes on the deeper MORF reports.
We send the PDF right away, then up to three short notes. Reply “unsubscribe” to any of them, any time.
How we handle your data → Privacy
The list of companies that name MORF as a peer is temporarily unavailable — recheck shortly.
One page per director: the seat, the committees and the fee table, read for one person at a time.
| Director | Role | FY2023 total |
|---|---|---|
| Gustav Christensen | Independent Director | $586,486 |
| Joseph P. Slattery | Independent Director | $560,736 |
| Martin Edwards | Independent Director | $547,486 |
| Nisha Nanda | Independent Director | $539,986 |
| Norbert Bischofberger | Independent Director | $545,736 |
| Susannah Gray | Independent Director | $547,486 |
| Timothy A. Springer | Independent Director | $539,986 |
Every insider equity transaction reported on Form 4 after the 2023 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.
| Insider | Role | Transaction date | Code | Shares | Price | Value | Security | Source |
|---|---|---|---|---|---|---|---|---|
| Martin Edwards | Director | 2024-06-04 | A | 23,168 | $0 | $0 | Derivative, Class A Common | Form 4 ↗ |
| Susannah Gray | Director | 2024-06-04 | A | 23,168 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Gustav Christensen | Director | 2024-06-04 | A | 23,168 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Joseph P. Slattery | Director | 2024-06-04 | A | 23,168 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Timothy A. Springer | Director | 2024-06-04 | A | 23,168 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Amir Nashat | Director | 2024-06-04 | A | 23,168 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Nisha Nanda | Director | 2024-06-04 | A | 23,168 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Norbert Bischofberger | Director | 2024-06-04 | A | 23,168 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Robert Farrell | SVP Finance and CAO | 2024-07-08 | D | 8,786 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Robert Farrell | SVP Finance and CAO | 2024-07-08 | D | 30,272 | 56 | 1,689,178 | Common | Form 4 ↗ |
| Robert Farrell | SVP Finance and CAO | 2024-07-08 | A | 8,786 | 4 | 37,912 | Common | Form 4 ↗ |
| Bruce Rogers | PRESIDENT | 2024-07-08 | D | 20,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Bruce Rogers | PRESIDENT | 2024-07-08 | D | 20,000 | 56 | 1,115,820 | Common | Form 4 ↗ |
| Praveen P. Tipirneni | Director | 2024-07-08 | D | 21,582 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Praveen P. Tipirneni | Director | 2024-07-08 | D | 21,582 | 56 | 1,204,075 | Common | Form 4 ↗ |
| Praveen P. Tipirneni | Director | 2024-07-08 | A | 21,582 | 4 | 93,128 | Common | Form 4 ↗ |
| Marc Schegerin | CFO and COO | 2024-07-08 | D | 43,936 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Marc Schegerin | CFO and COO | 2024-07-08 | D | 43,936 | 56 | 2,451,629 | Common | Form 4 ↗ |
| William DeVaul | General Counsel and Secretary | 2024-07-08 | D | 10,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| William DeVaul | General Counsel and Secretary | 2024-07-08 | D | 10,000 | 56 | 557,907 | Common | Form 4 ↗ |
| William DeVaul | General Counsel and Secretary | 2024-07-08 | A | 10,000 | 4 | 43,151 | Common | Form 4 ↗ |
| Marc Schegerin | CFO and COO | 2024-07-08 | A | 43,936 | 15 | 659,040 | Common | Form 4 ↗ |
| Bruce Rogers | PRESIDENT | 2024-07-08 | A | 20,000 | 4 | 86,302 | Common | Form 4 ↗ |
| Robert Farrell | SVP Finance and CAO | 2024-08-02 | D | 2,000 | 0 | 0 | Common | Form 4 ↗ |
| William DeVaul | General Counsel and Secretary | 2024-08-06 | D | 4,000 | 0 | 0 | Common | Form 4 ↗ |
| Robert Farrell | SVP Finance and CAO | 2024-08-16 | D | 62,400 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Robert Farrell | SVP Finance and CAO | 2024-08-16 | D | 6,940 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Robert Farrell | SVP Finance and CAO | 2024-08-16 | D | 38,025 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Robert Farrell | SVP Finance and CAO | 2024-08-16 | D | 88,800 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Robert Farrell | SVP Finance and CAO | 2024-08-16 | D | 76,320 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Robert Farrell | SVP Finance and CAO | 2024-08-16 | D | 60,288 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Robert Farrell | SVP Finance and CAO | 2024-08-16 | D | 75,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Robert Farrell | SVP Finance and CAO | 2024-08-16 | D | 87,500 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Robert Farrell | SVP Finance and CAO | 2024-08-16 | D | 26,750 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Robert Farrell | SVP Finance and CAO | 2024-08-16 | D | 12,000 | — | — | Common | Form 4 ↗ |
| Martin Edwards | Director | 2024-08-16 | D | 23,168 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Martin Edwards | Director | 2024-08-16 | D | 12,535 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Martin Edwards | Director | 2024-08-16 | D | 17,550 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Martin Edwards | Director | 2024-08-16 | D | 9,996 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Martin Edwards | Director | 2024-08-16 | D | 24,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Susannah Gray | Director | 2024-08-16 | D | 23,168 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Susannah Gray | Director | 2024-08-16 | D | 12,535 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Susannah Gray | Director | 2024-08-16 | D | 17,550 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Susannah Gray | Director | 2024-08-16 | D | 18,111 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Bruce Rogers | PRESIDENT | 2024-08-16 | D | 85,800 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Bruce Rogers | PRESIDENT | 2024-08-16 | D | 10,140 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Bruce Rogers | PRESIDENT | 2024-08-16 | D | 133,200 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Bruce Rogers | PRESIDENT | 2024-08-16 | D | 89,760 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Bruce Rogers | PRESIDENT | 2024-08-16 | D | 31,500 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Bruce Rogers | PRESIDENT | 2024-08-16 | D | 92,640 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Bruce Rogers | PRESIDENT | 2024-08-16 | D | 83,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Bruce Rogers | PRESIDENT | 2024-08-16 | D | 101,900 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Praveen P. Tipirneni | Director | 2024-08-16 | D | 136,800 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Praveen P. Tipirneni | Director | 2024-08-16 | D | 88,500 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Praveen P. Tipirneni | Director | 2024-08-16 | D | 177,024 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Praveen P. Tipirneni | Director | 2024-08-16 | D | 224,016 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Praveen P. Tipirneni | Director | 2024-08-16 | D | 205,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Praveen P. Tipirneni | Director | 2024-08-16 | D | 273,350 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Praveen P. Tipirneni | Director | 2024-08-16 | D | 339,561 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Praveen P. Tipirneni | Director | 2024-08-16 | D | 614,474 | — | — | Common, indirect | Form 4 ↗ |
| Praveen P. Tipirneni | Director | 2024-08-16 | D | 42,460 | — | — | Common | Form 4 ↗ |
| Marc Schegerin | CFO and COO | 2024-08-16 | D | 85,800 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Marc Schegerin | CFO and COO | 2024-08-16 | D | 9,380 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Marc Schegerin | CFO and COO | 2024-08-16 | D | 44,025 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Marc Schegerin | CFO and COO | 2024-08-16 | D | 133,200 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Gustav Christensen | Director | 2024-08-16 | D | 23,168 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Gustav Christensen | Director | 2024-08-16 | D | 12,535 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Gustav Christensen | Director | 2024-08-16 | D | 17,550 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Gustav Christensen | Director | 2024-08-16 | D | 9,150 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Gustav Christensen | Director | 2024-08-16 | D | 12,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Gustav Christensen | Director | 2024-08-16 | D | 24,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Norbert Bischofberger | Director | 2024-08-16 | D | 23,168 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Norbert Bischofberger | Director | 2024-08-16 | D | 12,535 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Norbert Bischofberger | Director | 2024-08-16 | D | 17,550 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Norbert Bischofberger | Director | 2024-08-16 | D | 9,888 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Norbert Bischofberger | Director | 2024-08-16 | D | 12,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Amir Nashat | Director | 2024-08-16 | D | 23,168 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Amir Nashat | Director | 2024-08-16 | D | 12,535 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Amir Nashat | Director | 2024-08-16 | D | 17,550 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Amir Nashat | Director | 2024-08-16 | D | 9,910 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Amir Nashat | Director | 2024-08-16 | D | 12,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Amir Nashat | Director | 2024-08-16 | D | 24,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Amir Nashat | Director | 2024-08-16 | D | 130,153 | — | — | Common, indirect | Form 4 ↗ |
| Amir Nashat | Director | 2024-08-16 | D | 1,860,498 | — | — | Common, indirect | Form 4 ↗ |
| Joseph P. Slattery | Director | 2024-08-16 | D | 23,168 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Joseph P. Slattery | Director | 2024-08-16 | D | 12,535 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Joseph P. Slattery | Director | 2024-08-16 | D | 17,550 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Joseph P. Slattery | Director | 2024-08-16 | D | 9,615 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Joseph P. Slattery | Director | 2024-08-16 | D | 12,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Joseph P. Slattery | Director | 2024-08-16 | D | 24,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Timothy A. Springer | Director | 2024-08-16 | D | 23,168 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Timothy A. Springer | Director | 2024-08-16 | D | 12,535 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Timothy A. Springer | Director | 2024-08-16 | D | 17,550 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Timothy A. Springer | Director | 2024-08-16 | D | 9,996 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Timothy A. Springer | Director | 2024-08-16 | D | 12,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Timothy A. Springer | Director | 2024-08-16 | D | 90,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Timothy A. Springer | Director | 2024-08-16 | D | 24,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Timothy A. Springer | Director | 2024-08-16 | D | 4,288 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Timothy A. Springer | Director | 2024-08-16 | D | 42,873 | — | — | Common | Form 4 ↗ |
| Timothy A. Springer | Director | 2024-08-16 | D | 2,768,893 | — | — | Common | Form 4 ↗ |
| Timothy A. Springer | Director | 2024-08-16 | D | 4,608,052 | — | — | Common | Form 4 ↗ |
| Bruce Rogers | PRESIDENT | 2024-08-16 | D | 54,714 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Bruce Rogers | PRESIDENT | 2024-08-16 | D | 149,883 | — | — | Common | Form 4 ↗ |
| Amir Nashat | Director | 2024-08-16 | D | 145 | — | — | Common | Form 4 ↗ |
| Marc Schegerin | CFO and COO | 2024-08-16 | D | 85,632 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Marc Schegerin | CFO and COO | 2024-08-16 | D | 83,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Marc Schegerin | CFO and COO | 2024-08-16 | D | 13,332 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Marc Schegerin | CFO and COO | 2024-08-16 | D | 37,907 | — | — | Common | Form 4 ↗ |
| Marc Schegerin | CFO and COO | 2024-08-16 | D | 86,544 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Bruce Rogers | PRESIDENT | 2024-08-16 | D | 45,675 | — | — | Derivative, Class A Common | Form 4 ↗ |
| William DeVaul | General Counsel and Secretary | 2024-08-16 | D | 44,400 | — | — | Derivative, Class A Common | Form 4 ↗ |
| William DeVaul | General Counsel and Secretary | 2024-08-16 | D | 6,500 | — | — | Derivative, Class A Common | Form 4 ↗ |
| William DeVaul | General Counsel and Secretary | 2024-08-16 | D | 32,850 | — | — | Derivative, Class A Common | Form 4 ↗ |
| William DeVaul | General Counsel and Secretary | 2024-08-16 | D | 69,600 | — | — | Derivative, Class A Common | Form 4 ↗ |
| William DeVaul | General Counsel and Secretary | 2024-08-16 | D | 62,160 | — | — | Derivative, Class A Common | Form 4 ↗ |
| William DeVaul | General Counsel and Secretary | 2024-08-16 | D | 57,792 | — | — | Derivative, Class A Common | Form 4 ↗ |
| William DeVaul | General Counsel and Secretary | 2024-08-16 | D | 75,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| William DeVaul | General Counsel and Secretary | 2024-08-16 | D | 74,700 | — | — | Derivative, Class A Common | Form 4 ↗ |
| William DeVaul | General Counsel and Secretary | 2024-08-16 | D | 15,508 | — | — | Derivative, Class A Common | Form 4 ↗ |
| William DeVaul | General Counsel and Secretary | 2024-08-16 | D | 103,855 | — | — | Derivative, Class A Common | Form 4 ↗ |
| William DeVaul | General Counsel and Secretary | 2024-08-16 | D | 19,587 | — | — | Common | Form 4 ↗ |
| Simon Peter Cooper | CMO | 2024-08-16 | D | 7,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Simon Peter Cooper | CMO | 2024-08-16 | D | 14,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Simon Peter Cooper | CMO | 2024-08-16 | D | 170,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Norbert Bischofberger | Director | 2024-08-16 | D | 24,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Gustav Christensen | Director | 2024-08-16 | D | 100,517 | — | — | Common | Form 4 ↗ |
| Praveen P. Tipirneni | Director | 2024-08-16 | D | 25,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Praveen P. Tipirneni | Director | 2024-08-16 | D | 206,400 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Joseph P. Slattery | Director | 2024-08-16 | D | 9,066 | — | — | Common | Form 4 ↗ |
| Martin Edwards | Director | 2024-08-16 | D | 2,376 | — | — | Common | Form 4 ↗ |
Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Bruce Rogers | Option | 48,250 | 44.75 | — |
| Marc Schegerin | Option | 18,800 | 15 | — |
| Praveen Tipirneni | RSU | 118,000 | — | 3,407,840 |
| Bruce Rogers | RSU | 60,900 | — | 1,758,792 |
| Marc Schegerin | RSU | 58,700 | — | 1,695,256 |
| Robert Farrell | RSU | 50,700 | — | 1,464,216 |
| Praveen Tipirneni | RSU | 37,500 | — | 1,083,000 |
| Bruce Rogers | RSU | 15,210 | — | 439,265 |
| Marc Schegerin | RSU | 14,070 | — | 406,342 |
| Robert Farrell | RSU | 10,410 | — | 300,641 |
| Praveen Tipirneni | Option | 136,456 | 31.72 | — |
| Praveen Tipirneni | Option | 116,675 | 44.75 | — |
| Praveen Tipirneni | Option | 55,521 | 30.19 | — |
| Praveen Tipirneni | Option | 11,390 | 15.42 | — |
| Bruce Rogers | Option | 69,190 | 31.72 | — |
| Bruce Rogers | Option | 19,032 | 23.74 | — |
| Bruce Rogers | Option | 22,480 | 30.19 | — |
| Bruce Rogers | Option | 4,246 | 15.42 | — |
| Marc Schegerin | Option | 66,711 | 31.72 | — |
| Marc Schegerin | Option | 44,600 | 44.75 | — |
| Marc Schegerin | Option | 22,480 | 30.19 | — |
| Robert Farrell | Option | 58,830 | 31.72 | — |
| Robert Farrell | Option | 31,400 | 44.75 | — |
| Robert Farrell | Option | 20,313 | 30.19 | — |
| Robert Farrell | Option | 3,646 | 15.42 | — |
We continue to reward our NEOs with competitive compensation packages that directly align pay with performance. The caliber of our performance in the areas of research, clinical and regulatory milestones drives our compensation structure, specifically the degree to which NEOs are granted equity and earn bonuses.
| CEO STI target (% of salary) | 55% |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | Aon |
| Clawback policy | true |
| Anti-hedging | true |
| Anti-pledging | true |
| Meeting year | Meeting date | For | Against | Abstain | Support | Outcome |
|---|---|---|---|---|---|---|
| 2024 | 2024-06-04 | 44,720,158 | 656,957 | 1,660 | 98.55% | Passed |
| 2023 | 2023-06-01 | 36,919,706 | 409,783 | 1,060 | 98.9% | Passed |
| 2022 | 2022-06-08 | 33,609,766 | 362,277 | 1,025 | 98.93% | Passed |
Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year's compensation.
| Meeting year | Meeting date | Approval — company's computation |
|---|---|---|
| 2024 | 2024-06-04 | 98.55%a |
| 2023 | 2023-06-01 | 98.9%b |
| 2022 | 2022-06-08 | 98.93%c |
a. Voting standard not stated in the filing.
b. Voting standard not stated in the filing.
c. Voting standard not stated in the filing.
Approval percentages are the company's own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Gustav ChristensenIndependent · Compensation (Chair) · Nominating and Corporate Governance | $86,500 | — | $499,986 | — | — | $586,486 |
| Joseph P. SlatteryIndependent · Audit (Chair) · Compensation | 60,750 | 0 | 499,986 | — | — | 560,736 |
| Martin EdwardsIndependent · Audit | 47,500 | 0 | 499,986 | — | — | 547,486 |
| Susannah GrayIndependent · Audit | 47,500 | — | 499,986 | — | — | 547,486 |
| Norbert BischofbergerIndependent · Compensation | 45,750 | 0 | 499,986 | — | — | 545,736 |
| Amir NashatIndependent · Nominating and Corporate Governance (Chair) | 45,000 | — | 499,986 | — | — | 544,986 |
| Nisha NandaIndependent | 40,000 | 0 | 499,986 | — | — | 539,986 |
| Timothy A. SpringerIndependent | 40,000 | 0 | 499,986 | — | — | 539,986 |
| Praveen P. TipirneniEmployee director | — | — | — | — | — | 0 |
| Annual cash retainer | $40,000 |
|---|---|
| Annual equity retainer | — |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 15,000 / 11,500 / 9,000 |
| Stock ownership guideline | — |
| Component | FY2023 |
|---|---|
| Cash retainers and fees | $413,000 |
| Equity awards (grant-date value) | $0 |
| All other compensation | $0 |
| Total cost of the board | $413,000 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.
Of the companies Morphic Holding names as compensation peers, which name it back in their own disclosed peer groups. A peer set the market reciprocates reads differently from one selected in a single direction.
Reciprocity shown where the peer's own current proxy has been read — each mark is cited in the register to that peer's filing. A dash means the peer's current proxy was read and names no reciprocal group including Morphic Holding.
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company's own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Scholar Rock Holding Corporation | 2025 | David Hallal | $637,500 | $22,518,500 | $7,624,988 | $452,293 | $33,300,927 |
| 2 | Cogent Biosciences, Inc. | 2025 | Andrew Robbins | 724,554 | 12,993,250 | 13,447,680 | 561,600 | 27,762,684 |
| 3 | Stoke Therapeutics, Inc. | 2025 | Ian Smith | 170,625 | 11,590,000 | 14,035,067 | 0 | 27,031,655 |
| 4 | Protagonist Therapeutics, Inc. | 2025 | Dinesh Patel | 715,500 | 5,839,204 | 5,618,010 | 686,880 | 12,871,506 |
| 5 | Arcus Biosciences, Inc. | 2025 | Terry Rosen | 775,000 | 2,199,450 | 6,008,860 | 658,750 | 9,656,813 |
| 6 | Morphic Holding | 2023 | Praveen Tipirneni | 613,502 | 3,742,960 | 4,121,756 | 412,966 | 8,907,684 |
| 7 | Kymera Therapeutics, Inc. | 2025 | Nello Mainolfi | 693,000 | 0 | 7,318,859 | 519,750 | 8,545,609 |
| 8 | Syndax Pharmaceuticals, Inc. | 2025 | Michael Metzger | 754,300 | 2,021,965 | 3,454,360 | 848,588 | 7,089,213 |
| 9 | RAPT Therapeutics, Inc. | 2024 | Brian Wong | 630,000 | 0 | 5,927,297 | 416,000 | 6,979,539 |
| 10 | Day One Biopharmaceuticals, Inc. | 2024 | Jeremy Bender | 680,000 | 2,700,280 | 2,664,697 | 501,800 | 6,560,577 |
| 11 | Arvinas, Inc. | 2025 | John Houston | 706,236 | 2,685,840 | 2,671,051 | 457,000 | 6,534,127 |
| 12 | NGM Biopharmaceuticals, Inc. | 2022 | David Woodhouse | 610,000 | 0 | 5,072,750 | 250,000 | 5,933,500 |
| 13 | Replimune Group, Inc. | 2026 | Sushil Patel | 700,000 | 3,376,003 | 1,448,325 | 315,000 | 5,845,982 |
| 14 | Pliant Therapeutics, Inc. | 2025 | Bernard Coulie | 682,000 | 1,810,250 | 2,713,750 | 204,600 | 5,462,901 |
| 15 | Prometheus Biosciences, Inc. | 2025 | Alexander Cumbo | 650,988 | 2,318,275 | 1,792,397 | 0 | 5,223,442 |
| 16 | Relay Therapeutics, Inc. | 2025 | Sanjiv Patel | 707,846 | 0 | 3,513,900 | 424,708 | 4,646,454 |
| 17 | Editas Medicine, Inc. | 2025 | Gilmore O'Neill | 686,574 | 0 | 1,282,937 | 375,164 | 2,353,655 |
| 18 | Gossamer Bio, Inc. | 2025 | Faheem Hasnain | 649,649 | 0 | 1,392,006 | 254,800 | 2,300,455 |
| 19 | Alector, Inc. | 2025 | Arnon Rosenthal | 678,100 | 422,876 | 558,216 | 325,488 | 1,995,018 |
| 20 | Mersana Therapeutics, Inc. | 2024 | Michael Huber | 632,500 | 133,635 | 518,044 | 322,575 | 1,613,754 |
| — | C4 Therapeutics, Inc. | — | — | — | — | — | — | not in coverage universe |
Each peer's compensation is from its most recently filed proxy; fiscal years differ by company. Each peer's figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
| Company | Annual incentive payout | Long-term vehicle mix | PSU measures include TSR | Compensation consultant |
|---|---|---|---|---|
| Morphic Holding | 120% | Stock Options 50 · RSU 50 | not disclosed | Aon |
| Alector, Inc. | 80% | not disclosed | not disclosed | Pearl Meyer & Partners, LLC |
| Arcus Biosciences, Inc. | 100% | Options 67 · RSU 33 | not disclosed | Radford |
| Arvinas, Inc. | 108% | Options 50 · RSU 50 | not disclosed | Aon (Aon's Human Capital Solutions practice, a division of Aon plc) |
| C4 Therapeutics, Inc. | not disclosed | not disclosed | not disclosed | not disclosed |
| Cogent Biosciences, Inc. | 135% | not disclosed | No | Compensia |
| Day One Biopharmaceuticals, Inc. | 123%% | Stock Options 50 · RSUs 50 | not disclosed | Compensia Inc. |
| Editas Medicine, Inc. | 91% | Options 100 | not disclosed | Pearl Meyer & Partners, LLC |
| Gossamer Bio, Inc. | 65% | not disclosed | No | Alpine Rewards |
| Kymera Therapeutics, Inc. | 125% | not disclosed | No | Alpine Rewards |
| Mersana Therapeutics, Inc. | not disclosed | Option 75 · RSU 25 | not disclosed | Pearl Meyer & Partners, LLC |
| NGM Biopharmaceuticals, Inc. | 75% | Option 100 | not disclosed | Aon |
| Pliant Therapeutics, Inc. | not disclosed | Options 67 · RSU 33 | not disclosed | Alpine Rewards |
| Prometheus Biosciences, Inc. | 100% | not disclosed | No | Radford (AON Hewitt) |
| Protagonist Therapeutics, Inc. | 160% | Options 50 · RSU 50 | not disclosed | Aon Human Capital Solutions |
| RAPT Therapeutics, Inc. | 120% | Option 100 | not disclosed | Aon plc/Radford |
| Relay Therapeutics, Inc. | 100% | Option 100 | not disclosed | Aon's Human Capital Solutions practice, a division of Aon plc |
| Replimune Group, Inc. | not disclosed | not disclosed | No | Pearl Meyer |
| Scholar Rock Holding Corporation | not disclosed | not disclosed | No | Pay Governance |
| Stoke Therapeutics, Inc. | not disclosed | not disclosed | not disclosed | Aon |
| Syndax Pharmaceuticals, Inc. | 150% | Options 34 · PSU 33 · RSU 33 | Yes — Company's three-year total shareholder return (TSR) as measured against the Nasdaq Biotechnology Index components TSRs | Aon |
Read from each company's Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company's filing does not state the item.
Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.
Each figure's location is given both for the eye (section · page · table · row · column) and for a script (table/row/column index and exact character span in the filed document). Any figure can be independently confirmed against the source.
| # | Supports | Document | Filed | Accession | Location in document |
|---|---|---|---|---|---|
| 1 | Section 01, Praveen Tipirneni | DEF 14A | 2024-04-25 | 0001679363-24-000035 | Section “Executive Compensation”. As printed: 8,907,684. Filing ↗machine: r3 · c48 · span 295049–295058 |
| 2 | Section 01, Bruce Rogers | DEF 14A | 2024-04-25 | 0001679363-24-000035 | Section “Executive Compensation”. As printed: 4,879,024. Filing ↗machine: r7 · c48 · span 302445–302454 |
| 3 | Section 01, Marc Schegerin | DEF 14A | 2024-04-25 | 0001679363-24-000035 | Section “Executive Compensation”. As printed: 4,646,272. Filing ↗machine: r11 · c48 · span 310060–310069 |
| 4 | Section 01, Robert Farrell | DEF 14A | 2024-04-25 | 0001679363-24-000035 | Section “Executive Compensation”. As printed: 4,030,708. Filing ↗machine: r15 · c48 · span 317486–317495 |
| 5 | Section 08, Gustav Christensen | DEF 14A | 2024-04-25 | 0001679363-24-000035 | Section “Director Compensation”. As printed: 586,486. Filing ↗machine: span 179576–179707 |
| 6 | Section 08, Joseph P. Slattery | DEF 14A | 2024-04-25 | 0001679363-24-000035 | Section “Director Compensation”. As printed: 560,736. Filing ↗machine: span 187623–187754 |
| 7 | Section 08, Martin Edwards | DEF 14A | 2024-04-25 | 0001679363-24-000035 | Section “Director Compensation”. As printed: 547,486. Filing ↗machine: span 180982–181113 |
| 8 | Section 08, Susannah Gray | DEF 14A | 2024-04-25 | 0001679363-24-000035 | Section “Director Compensation”. As printed: 547,486. Filing ↗machine: span 182726–182857 |
| 9 | Section 08, Norbert Bischofberger | DEF 14A | 2024-04-25 | 0001679363-24-000035 | Section “Director Compensation”. As printed: 545,736. Filing ↗machine: span 177827–177958 |
| 10 | Section 08, Amir Nashat | DEF 14A | 2024-04-25 | 0001679363-24-000035 | Section “Director Compensation”. As printed: 544,986. Filing ↗machine: span 185874–186005 |
| 11 | Section 08, Nisha Nanda | DEF 14A | 2024-04-25 | 0001679363-24-000035 | Section “Director Compensation”. As printed: 539,986. Filing ↗machine: span 184130–184261 |
| 12 | Section 08, Timothy A. Springer | DEF 14A | 2024-04-25 | 0001679363-24-000035 | Section “Director Compensation”. As printed: 539,986. Filing ↗machine: span 189372–189503 |
| 13 | Section 08, Praveen P. Tipirneni | DEF 14A | 2024-04-25 | 0001679363-24-000035 | Section “Director Compensation”. As printed: 0. Filing ↗ |
| 14 | Section 02, Martin Edwards 2024-06-04 | Form 4 | 2024-06-05 | 0001415889-24-015691 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 15 | Section 02, Susannah Gray 2024-06-04 | Form 4 | 2024-06-05 | 0001415889-24-015666 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 16 | Section 02, Gustav Christensen 2024-06-04 | Form 4 | 2024-06-05 | 0001415889-24-015663 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 17 | Section 02, Joseph P. Slattery 2024-06-04 | Form 4 | 2024-06-05 | 0001415889-24-015669 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 18 | Section 02, Timothy A. Springer 2024-06-04 | Form 4 | 2024-06-05 | 0001415889-24-015670 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 19 | Section 02, Amir Nashat 2024-06-04 | Form 4 | 2024-06-05 | 0001415889-24-015668 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 20 | Section 02, Nisha Nanda 2024-06-04 | Form 4 | 2024-06-05 | 0001415889-24-015667 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 21 | Section 02, Norbert Bischofberger 2024-06-04 | Form 4 | 2024-06-05 | 0001415889-24-015664 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 22 | Section 02, Robert Farrell 2024-07-08 | Form 4 | 2024-07-10 | 0001415889-24-019469 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 23 | Section 02, Robert Farrell 2024-07-08 | Form 4 | 2024-07-10 | 0001415889-24-019469 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 24 | Section 02, Robert Farrell 2024-07-08 | Form 4 | 2024-07-10 | 0001415889-24-019469 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 25 | Section 02, Bruce Rogers 2024-07-08 | Form 4 | 2024-07-10 | 0001415889-24-019473 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 26 | Section 02, Bruce Rogers 2024-07-08 | Form 4 | 2024-07-10 | 0001415889-24-019473 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 27 | Section 02, Praveen P. Tipirneni 2024-07-08 | Form 4 | 2024-07-10 | 0001415889-24-019471 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 28 | Section 02, Praveen P. Tipirneni 2024-07-08 | Form 4 | 2024-07-10 | 0001415889-24-019471 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 29 | Section 02, Praveen P. Tipirneni 2024-07-08 | Form 4 | 2024-07-10 | 0001415889-24-019471 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 30 | Section 02, Marc Schegerin 2024-07-08 | Form 4 | 2024-07-10 | 0001415889-24-019472 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 31 | Section 02, Marc Schegerin 2024-07-08 | Form 4 | 2024-07-10 | 0001415889-24-019472 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 32 | Section 02, William DeVaul 2024-07-08 | Form 4 | 2024-07-10 | 0001415889-24-019468 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 33 | Section 02, William DeVaul 2024-07-08 | Form 4 | 2024-07-10 | 0001415889-24-019468 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 34 | Section 02, William DeVaul 2024-07-08 | Form 4 | 2024-07-10 | 0001415889-24-019468 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 35 | Section 02, Marc Schegerin 2024-07-08 | Form 4 | 2024-07-10 | 0001415889-24-019472 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 36 | Section 02, Bruce Rogers 2024-07-08 | Form 4 | 2024-07-10 | 0001415889-24-019473 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 37 | Section 02, Robert Farrell 2024-08-02 | Form 4 | 2024-08-02 | 0001415889-24-020683 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 38 | Section 02, William DeVaul 2024-08-06 | Form 4 | 2024-08-07 | 0001415889-24-020947 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 39 | Section 02, Robert Farrell 2024-08-16 | Form 4 | 2024-08-20 | 0001415889-24-021739 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 40 | Section 02, Robert Farrell 2024-08-16 | Form 4 | 2024-08-20 | 0001415889-24-021739 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 41 | Section 02, Robert Farrell 2024-08-16 | Form 4 | 2024-08-20 | 0001415889-24-021739 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 42 | Section 02, Robert Farrell 2024-08-16 | Form 4 | 2024-08-20 | 0001415889-24-021739 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 43 | Section 02, Robert Farrell 2024-08-16 | Form 4 | 2024-08-20 | 0001415889-24-021739 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 44 | Section 02, Robert Farrell 2024-08-16 | Form 4 | 2024-08-20 | 0001415889-24-021739 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 45 | Section 02, Robert Farrell 2024-08-16 | Form 4 | 2024-08-20 | 0001415889-24-021739 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 46 | Section 02, Robert Farrell 2024-08-16 | Form 4 | 2024-08-20 | 0001415889-24-021739 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 47 | Section 02, Robert Farrell 2024-08-16 | Form 4 | 2024-08-20 | 0001415889-24-021739 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 48 | Section 02, Robert Farrell 2024-08-16 | Form 4 | 2024-08-20 | 0001415889-24-021739 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 49 | Section 02, Martin Edwards 2024-08-16 | Form 4 | 2024-08-21 | 0001415889-24-021823 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 50 | Section 02, Martin Edwards 2024-08-16 | Form 4 | 2024-08-21 | 0001415889-24-021823 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 51 | Section 02, Martin Edwards 2024-08-16 | Form 4 | 2024-08-21 | 0001415889-24-021823 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 52 | Section 02, Martin Edwards 2024-08-16 | Form 4 | 2024-08-21 | 0001415889-24-021823 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 53 | Section 02, Martin Edwards 2024-08-16 | Form 4 | 2024-08-21 | 0001415889-24-021823 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 54 | Section 02, Susannah Gray 2024-08-16 | Form 4 | 2024-08-20 | 0001415889-24-021759 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 55 | Section 02, Susannah Gray 2024-08-16 | Form 4 | 2024-08-20 | 0001415889-24-021759 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 56 | Section 02, Susannah Gray 2024-08-16 | Form 4 | 2024-08-20 | 0001415889-24-021759 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 57 | Section 02, Susannah Gray 2024-08-16 | Form 4 | 2024-08-20 | 0001415889-24-021759 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 58 | Section 02, Bruce Rogers 2024-08-16 | Form 4 | 2024-08-20 | 0001415889-24-021746 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 59 | Section 02, Bruce Rogers 2024-08-16 | Form 4 | 2024-08-20 | 0001415889-24-021746 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 60 | Section 02, Bruce Rogers 2024-08-16 | Form 4 | 2024-08-20 | 0001415889-24-021746 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 61 | Section 02, Bruce Rogers 2024-08-16 | Form 4 | 2024-08-20 | 0001415889-24-021746 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 62 | Section 02, Bruce Rogers 2024-08-16 | Form 4 | 2024-08-20 | 0001415889-24-021746 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 63 | Section 02, Bruce Rogers 2024-08-16 | Form 4 | 2024-08-20 | 0001415889-24-021746 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 64 | Section 02, Bruce Rogers 2024-08-16 | Form 4 | 2024-08-20 | 0001415889-24-021746 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 65 | Section 02, Bruce Rogers 2024-08-16 | Form 4 | 2024-08-20 | 0001415889-24-021746 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 66 | Section 02, Praveen P. Tipirneni 2024-08-16 | Form 4 | 2024-08-20 | 0001415889-24-021762 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 67 | Section 02, Praveen P. Tipirneni 2024-08-16 | Form 4 | 2024-08-20 | 0001415889-24-021762 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 68 | Section 02, Praveen P. Tipirneni 2024-08-16 | Form 4 | 2024-08-20 | 0001415889-24-021762 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 69 | Section 02, Praveen P. Tipirneni 2024-08-16 | Form 4 | 2024-08-20 | 0001415889-24-021762 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 70 | Section 02, Praveen P. Tipirneni 2024-08-16 | Form 4 | 2024-08-20 | 0001415889-24-021762 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 71 | Section 02, Praveen P. Tipirneni 2024-08-16 | Form 4 | 2024-08-20 | 0001415889-24-021762 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 72 | Section 02, Praveen P. Tipirneni 2024-08-16 | Form 4 | 2024-08-20 | 0001415889-24-021762 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 73 | Section 02, Praveen P. Tipirneni 2024-08-16 | Form 4 | 2024-08-20 | 0001415889-24-021762 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 74 | Section 02, Praveen P. Tipirneni 2024-08-16 | Form 4 | 2024-08-20 | 0001415889-24-021762 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 75 | Section 02, Marc Schegerin 2024-08-16 | Form 4 | 2024-08-20 | 0001415889-24-021741 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 76 | Section 02, Marc Schegerin 2024-08-16 | Form 4 | 2024-08-20 | 0001415889-24-021741 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 77 | Section 02, Marc Schegerin 2024-08-16 | Form 4 | 2024-08-20 | 0001415889-24-021741 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 78 | Section 02, Marc Schegerin 2024-08-16 | Form 4 | 2024-08-20 | 0001415889-24-021741 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 79 | Section 02, Gustav Christensen 2024-08-16 | Form 4 | 2024-08-20 | 0001415889-24-021756 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 80 | Section 02, Gustav Christensen 2024-08-16 | Form 4 | 2024-08-20 | 0001415889-24-021756 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 81 | Section 02, Gustav Christensen 2024-08-16 | Form 4 | 2024-08-20 | 0001415889-24-021756 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 82 | Section 02, Gustav Christensen 2024-08-16 | Form 4 | 2024-08-20 | 0001415889-24-021756 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 83 | Section 02, Gustav Christensen 2024-08-16 | Form 4 | 2024-08-20 | 0001415889-24-021756 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 84 | Section 02, Gustav Christensen 2024-08-16 | Form 4 | 2024-08-20 | 0001415889-24-021756 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 85 | Section 02, Norbert Bischofberger 2024-08-16 | Form 4 | 2024-08-20 | 0001415889-24-021754 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 86 | Section 02, Norbert Bischofberger 2024-08-16 | Form 4 | 2024-08-20 | 0001415889-24-021754 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 87 | Section 02, Norbert Bischofberger 2024-08-16 | Form 4 | 2024-08-20 | 0001415889-24-021754 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 88 | Section 02, Norbert Bischofberger 2024-08-16 | Form 4 | 2024-08-20 | 0001415889-24-021754 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 89 | Section 02, Norbert Bischofberger 2024-08-16 | Form 4 | 2024-08-20 | 0001415889-24-021754 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 90 | Section 02, Amir Nashat 2024-08-16 | Form 4 | 2024-08-20 | 0001415889-24-021767 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 91 | Section 02, Amir Nashat 2024-08-16 | Form 4 | 2024-08-20 | 0001415889-24-021767 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 92 | Section 02, Amir Nashat 2024-08-16 | Form 4 | 2024-08-20 | 0001415889-24-021767 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 93 | Section 02, Amir Nashat 2024-08-16 | Form 4 | 2024-08-20 | 0001415889-24-021767 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 94 | Section 02, Amir Nashat 2024-08-16 | Form 4 | 2024-08-20 | 0001415889-24-021767 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 95 | Section 02, Amir Nashat 2024-08-16 | Form 4 | 2024-08-20 | 0001415889-24-021767 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 96 | Section 02, Amir Nashat 2024-08-16 | Form 4 | 2024-08-20 | 0001415889-24-021767 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 97 | Section 02, Amir Nashat 2024-08-16 | Form 4 | 2024-08-20 | 0001415889-24-021767 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 98 | Section 02, Joseph P. Slattery 2024-08-16 | Form 4 | 2024-08-20 | 0001415889-24-021769 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 99 | Section 02, Joseph P. Slattery 2024-08-16 | Form 4 | 2024-08-20 | 0001415889-24-021769 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 100 | Section 02, Joseph P. Slattery 2024-08-16 | Form 4 | 2024-08-20 | 0001415889-24-021769 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 101 | Section 02, Joseph P. Slattery 2024-08-16 | Form 4 | 2024-08-20 | 0001415889-24-021769 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 102 | Section 02, Joseph P. Slattery 2024-08-16 | Form 4 | 2024-08-20 | 0001415889-24-021769 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 103 | Section 02, Joseph P. Slattery 2024-08-16 | Form 4 | 2024-08-20 | 0001415889-24-021769 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 104 | Section 02, Timothy A. Springer 2024-08-16 | Form 4 | 2024-08-20 | 0001415889-24-021765 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 105 | Section 02, Timothy A. Springer 2024-08-16 | Form 4 | 2024-08-20 | 0001415889-24-021765 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 106 | Section 02, Timothy A. Springer 2024-08-16 | Form 4 | 2024-08-20 | 0001415889-24-021765 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 107 | Section 02, Timothy A. Springer 2024-08-16 | Form 4 | 2024-08-20 | 0001415889-24-021765 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 108 | Section 02, Timothy A. Springer 2024-08-16 | Form 4 | 2024-08-20 | 0001415889-24-021765 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 109 | Section 02, Timothy A. Springer 2024-08-16 | Form 4 | 2024-08-20 | 0001415889-24-021765 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 110 | Section 02, Timothy A. Springer 2024-08-16 | Form 4 | 2024-08-20 | 0001415889-24-021765 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 111 | Section 02, Timothy A. Springer 2024-08-16 | Form 4 | 2024-08-20 | 0001415889-24-021765 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 112 | Section 02, Timothy A. Springer 2024-08-16 | Form 4 | 2024-08-20 | 0001415889-24-021765 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 113 | Section 02, Timothy A. Springer 2024-08-16 | Form 4 | 2024-08-20 | 0001415889-24-021765 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 114 | Section 02, Timothy A. Springer 2024-08-16 | Form 4 | 2024-08-20 | 0001415889-24-021765 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 115 | Section 02, Bruce Rogers 2024-08-16 | Form 4 | 2024-08-20 | 0001415889-24-021746 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 116 | Section 02, Bruce Rogers 2024-08-16 | Form 4 | 2024-08-20 | 0001415889-24-021746 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 117 | Section 02, Amir Nashat 2024-08-16 | Form 4 | 2024-08-20 | 0001415889-24-021767 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 118 | Section 02, Marc Schegerin 2024-08-16 | Form 4 | 2024-08-20 | 0001415889-24-021741 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 119 | Section 02, Marc Schegerin 2024-08-16 | Form 4 | 2024-08-20 | 0001415889-24-021741 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 120 | Section 02, Marc Schegerin 2024-08-16 | Form 4 | 2024-08-20 | 0001415889-24-021741 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 121 | Section 02, Marc Schegerin 2024-08-16 | Form 4 | 2024-08-20 | 0001415889-24-021741 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 122 | Section 02, Marc Schegerin 2024-08-16 | Form 4 | 2024-08-20 | 0001415889-24-021741 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 123 | Section 02, Bruce Rogers 2024-08-16 | Form 4 | 2024-08-20 | 0001415889-24-021746 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 124 | Section 02, William DeVaul 2024-08-16 | Form 4 | 2024-08-20 | 0001415889-24-021750 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 125 | Section 02, William DeVaul 2024-08-16 | Form 4 | 2024-08-20 | 0001415889-24-021750 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 126 | Section 02, William DeVaul 2024-08-16 | Form 4 | 2024-08-20 | 0001415889-24-021750 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 127 | Section 02, William DeVaul 2024-08-16 | Form 4 | 2024-08-20 | 0001415889-24-021750 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 128 | Section 02, William DeVaul 2024-08-16 | Form 4 | 2024-08-20 | 0001415889-24-021750 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 129 | Section 02, William DeVaul 2024-08-16 | Form 4 | 2024-08-20 | 0001415889-24-021750 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 130 | Section 02, William DeVaul 2024-08-16 | Form 4 | 2024-08-20 | 0001415889-24-021750 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 131 | Section 02, William DeVaul 2024-08-16 | Form 4 | 2024-08-20 | 0001415889-24-021750 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 132 | Section 02, William DeVaul 2024-08-16 | Form 4 | 2024-08-20 | 0001415889-24-021750 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 133 | Section 02, William DeVaul 2024-08-16 | Form 4 | 2024-08-20 | 0001415889-24-021750 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 134 | Section 02, William DeVaul 2024-08-16 | Form 4 | 2024-08-20 | 0001415889-24-021750 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 135 | Section 02, Simon Peter Cooper 2024-08-16 | Form 4 | 2024-08-20 | 0001415889-24-021752 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 136 | Section 02, Simon Peter Cooper 2024-08-16 | Form 4 | 2024-08-20 | 0001415889-24-021752 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 137 | Section 02, Simon Peter Cooper 2024-08-16 | Form 4 | 2024-08-20 | 0001415889-24-021752 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 138 | Section 02, Norbert Bischofberger 2024-08-16 | Form 4 | 2024-08-20 | 0001415889-24-021754 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 139 | Section 02, Gustav Christensen 2024-08-16 | Form 4 | 2024-08-20 | 0001415889-24-021756 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 140 | Section 02, Praveen P. Tipirneni 2024-08-16 | Form 4 | 2024-08-20 | 0001415889-24-021762 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 141 | Section 02, Praveen P. Tipirneni 2024-08-16 | Form 4 | 2024-08-20 | 0001415889-24-021762 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 142 | Section 02, Joseph P. Slattery 2024-08-16 | Form 4 | 2024-08-20 | 0001415889-24-021769 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 143 | Section 02, Martin Edwards 2024-08-16 | Form 4 | 2024-08-21 | 0001415889-24-021823 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 144 | Section 06, 2024 vote | Form 8-K | 2024-06-05 | 0001679363-24-000042 | Item 5.07 · say-on-pay result. As reported: 98.55% (votes for as printed: 44,720,158). Filing ↗ |
| 145 | Section 06, 2023 vote | Form 8-K | 2023-06-02 | 0001679363-23-000048 | Item 5.07 · say-on-pay result. As reported: 98.9% (votes for as printed: 36,919,706). Filing ↗ |
| 146 | Section 06, 2022 vote | Form 8-K | 2022-06-09 | 0001679363-22-000034 | Item 5.07 · say-on-pay result. As reported: 98.93% (votes for as printed: 33,609,766). Filing ↗ |
| 147 | Section 01 trend, Δ column (computed) | Computed | — | — | Δ = current-FY total − prior-FY total per named officer.machine: formula: Δ = FY(n) − FY(n−1) |
| 148 | Section 09b board cost (computed) | Computed | — | — | Cash 413,000 + equity 0 + all other 0 = 413,000, summed across the director compensation table rows.machine: formula: Σ = 413,000 |
| 149 | Scholar Rock Holding Corporation, Section 10b CEO total | DEF 14A | 2026-04-22 | 0001104659-26-046917 | CEO total compensation as printed in Scholar Rock Holding Corporation's own proxy. As printed: 33,300,927. Filing ↗machine: r1 · c47 · span 363867–363877 |
| 150 | Cogent Biosciences, Inc., Section 10b CEO total | DEF 14A | 2026-04-23 | 0001193125-26-173834 | CEO total compensation as printed in Cogent Biosciences, Inc.'s own proxy. As printed: 27,762,684. Filing ↗machine: r2 · c39 · span 369353–369363 |
| 151 | Stoke Therapeutics, Inc., Section 10b CEO total | DEF 14A | 2026-04-22 | 0001193125-26-170362 | CEO total compensation as printed in Stoke Therapeutics, Inc.'s own proxy. As printed: 27,031,655. Filing ↗machine: r2 · c31 · span 335841–335851 |
| 152 | Protagonist Therapeutics, Inc., Section 10b CEO total | DEF 14A | 2026-04-28 | 0001104659-26-050429 | CEO total compensation as printed in Protagonist Therapeutics, Inc.'s own proxy. As printed: 12,871,506. Filing ↗machine: r1 · c47 · span 613195–613205 |
| 153 | Arcus Biosciences, Inc., Section 10b CEO total | DEF 14A | 2026-04-21 | 0001724521-26-000025 | CEO total compensation as printed in Arcus Biosciences, Inc.'s own proxy. As printed: 9,656,813. Filing ↗machine: r2 · c48 · span 403740–403749 |
| 154 | Morphic Holding (subject), Section 10b CEO total | DEF 14A | 2024-04-25 | 0001679363-24-000035 | CEO total compensation as printed in Morphic Holding's own proxy. As printed: 8,907,684. Filing ↗machine: r3 · c48 · span 295049–295058 |
| 155 | Kymera Therapeutics, Inc., Section 10b CEO total | DEF 14A | 2026-04-29 | 0001193125-26-191495 | CEO total compensation as printed in Kymera Therapeutics, Inc.'s own proxy. As printed: 8,545,609. Filing ↗machine: r2 · c14 · span 676137–676146 |
| 156 | Syndax Pharmaceuticals, Inc., Section 10b CEO total | DEF 14A | 2026-04-30 | 0001193125-26-197859 | CEO total compensation as printed in Syndax Pharmaceuticals, Inc.'s own proxy. As printed: 7,089,213. Filing ↗machine: span 936322–936331 |
| 157 | RAPT Therapeutics, Inc., Section 10b CEO total | DEF 14A | 2025-04-14 | 0000950170-25-053517 | CEO total compensation as printed in RAPT Therapeutics, Inc.'s own proxy. As printed: 6,979,539. Filing ↗machine: r2 · c23 · span 816852–816861 |
| 158 | Day One Biopharmaceuticals, Inc., Section 10b CEO total | DEF 14A | 2025-04-11 | 0001140361-25-013462 | CEO total compensation as printed in Day One Biopharmaceuticals, Inc.'s own proxy. As printed: 6,560,577. Filing ↗machine: r2 · c21 · span 526324–526333 |
| 159 | Arvinas, Inc., Section 10b CEO total | DEF 14A | 2026-04-29 | 0001628280-26-028156 | CEO total compensation as printed in Arvinas, Inc.'s own proxy. As printed: 6,534,127. Filing ↗machine: t20 · r3 · c22 · span 471921–471930 |
| 160 | NGM Biopharmaceuticals, Inc., Section 10b CEO total | DEF 14A | 2023-03-29 | 0001628280-23-009712 | CEO total compensation as printed in NGM Biopharmaceuticals, Inc.'s own proxy. As printed: 5,933,500. Filing ↗machine: r2 · c42 · span 406619–406628 |
| 161 | Replimune Group, Inc., Section 10b CEO total | DEF 14A | 2026-07-29 | 0001104659-26-087650 | CEO total compensation as printed in Replimune Group, Inc.'s own proxy. As printed: 5,845,982. Filing ↗machine: r1 · c41 · span 430765–430774 |
| 162 | Pliant Therapeutics, Inc., Section 10b CEO total | DEF 14A | 2026-04-22 | 0001746473-26-000076 | CEO total compensation as printed in Pliant Therapeutics, Inc.'s own proxy. As printed: 5,462,901. Filing ↗machine: r2 · c48 · span 436933–436942 |
| 163 | Prometheus Biosciences, Inc., Section 10b CEO total | DEF 14A | 2026-04-23 | 0001193125-26-173642 | CEO total compensation as printed in Prometheus Biosciences, Inc.'s own proxy. As printed: 5,223,442. Filing ↗machine: r2 · c25 · span 472915–472924 |
| 164 | Relay Therapeutics, Inc., Section 10b CEO total | DEF 14A | 2026-04-28 | 0001193125-26-186929 | CEO total compensation as printed in Relay Therapeutics, Inc.'s own proxy. As printed: 4,646,454. Filing ↗machine: r2 · c29 · span 660153–660162 |
| 165 | Editas Medicine, Inc., Section 10b CEO total | DEF 14A | 2026-04-28 | 0001650664-26-000037 | CEO total compensation as printed in Editas Medicine, Inc.'s own proxy. As printed: 2,353,655. Filing ↗machine: t42 · r2 · c12 · span 545455–545464 |
| 166 | Gossamer Bio, Inc., Section 10b CEO total | DEF 14A | 2026-04-24 | 0001728117-26-000027 | CEO total compensation as printed in Gossamer Bio, Inc.'s own proxy. As printed: 2,300,455. Filing ↗machine: r2 · c48 · span 378559–378568 |
| 167 | Alector, Inc., Section 10b CEO total | DEF 14A | 2026-04-28 | 0001193125-26-186928 | CEO total compensation as printed in Alector, Inc.'s own proxy. As printed: 1,995,018. Filing ↗machine: span 1038665–1038674 |
| 168 | Mersana Therapeutics, Inc., Section 10b CEO total | DEF 14A | 2025-04-29 | 0001104659-25-040448 | CEO total compensation as printed in Mersana Therapeutics, Inc.'s own proxy. As printed: 1,613,754. Filing ↗machine: r1 · c41 · span 608188–608197 |
| 169 | Section 10a, Alector, Inc. reciprocity | DEF 14A | — | 0001193125-26-186928 | Alector, Inc.'s most recent proxy was read; its disclosed peer group does not include Morphic Holding. Filing ↗ |
| 170 | Section 10a, Scholar Rock Holding Corporation reciprocity | DEF 14A | — | 0001104659-26-046917 | Scholar Rock Holding Corporation's most recent proxy was read; its disclosed peer group does not include Morphic Holding. Filing ↗ |
| 171 | Section 10a, Pliant Therapeutics, Inc. reciprocity | DEF 14A | — | 0001746473-26-000076 | Pliant Therapeutics, Inc.'s most recent proxy was read; its disclosed peer group does not include Morphic Holding. Filing ↗ |
| 172 | Section 10a, Arvinas, Inc. reciprocity | DEF 14A | — | 0001628280-26-028156 | Arvinas, Inc.'s most recent proxy was read; its disclosed peer group does not include Morphic Holding. Filing ↗ |
| 173 | Section 10a, Kymera Therapeutics, Inc. reciprocity | DEF 14A | — | 0001193125-26-191495 | Kymera Therapeutics, Inc.'s most recent proxy was read; its disclosed peer group does not include Morphic Holding. Filing ↗ |
| 174 | Section 10a, Day One Biopharmaceuticals, Inc. reciprocity | DEF 14A | — | 0001140361-25-013462 | Day One Biopharmaceuticals, Inc.'s most recent proxy was read; its disclosed peer group does not include Morphic Holding. Filing ↗ |
| 175 | Section 10a, Editas Medicine, Inc. reciprocity | DEF 14A | — | 0001650664-26-000037 | Editas Medicine, Inc.'s most recent proxy was read; its disclosed peer group does not include Morphic Holding. Filing ↗ |
| 176 | Section 10a, Mersana Therapeutics, Inc. reciprocity | DEF 14A | — | 0001104659-25-040448 | Mersana Therapeutics, Inc.'s most recent proxy was read; its disclosed peer group does not include Morphic Holding. Filing ↗ |
| 177 | Section 10a, NGM Biopharmaceuticals, Inc. reciprocity | DEF 14A | — | 0001628280-23-009712 | NGM Biopharmaceuticals, Inc.'s most recent proxy was read; its disclosed peer group does not include Morphic Holding. Filing ↗ |
| 178 | Section 10a, Protagonist Therapeutics, Inc. reciprocity | DEF 14A | — | 0001104659-26-050429 | Protagonist Therapeutics, Inc.'s most recent proxy was read; its disclosed peer group does not include Morphic Holding. Filing ↗ |
| 179 | Section 10a, Relay Therapeutics, Inc. reciprocity | DEF 14A | — | 0001193125-26-186929 | Relay Therapeutics, Inc.'s most recent proxy was read; its disclosed peer group does not include Morphic Holding. Filing ↗ |
| 180 | Section 10a, Stoke Therapeutics, Inc. reciprocity | DEF 14A | — | 0001193125-26-170362 | Stoke Therapeutics, Inc.'s most recent proxy was read; its disclosed peer group does not include Morphic Holding. Filing ↗ |
| 181 | Section 10a, Syndax Pharmaceuticals, Inc. reciprocity | DEF 14A | — | 0001193125-26-197859 | Syndax Pharmaceuticals, Inc.'s most recent proxy was read; its disclosed peer group does not include Morphic Holding. Filing ↗ |
| 182 | Section 10a, Cogent Biosciences, Inc. reciprocity | DEF 14A | — | 0001193125-26-173834 | Cogent Biosciences, Inc.'s most recent proxy was read; its disclosed peer group does not include Morphic Holding. Filing ↗ |
| 183 | Section 10a, Gossamer Bio, Inc. reciprocity | DEF 14A | — | 0001728117-26-000027 | Gossamer Bio, Inc.'s most recent proxy was read; its disclosed peer group does not include Morphic Holding. Filing ↗ |
The Pay Desk — the free weekly executive pay briefing, one company at a time, every number traceable to a public filing.
You'll confirm on The Pay Desk's sign-up page.